Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug 24;5(10):e1224044.
doi: 10.1080/2162402X.2016.1224044. eCollection 2016.

Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement

Affiliations

Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement

Pauline Gravelle et al. Oncoimmunology. .

Abstract

Upregulation of T cell immunoglobulin-3 (TIM-3) has been associated with negative regulation of the immune response in chronic infection and cancer, including lymphoma. Here, we investigated the possible correlation between TIM-3 expression by ex vivo cytotoxic T cells (CTL) from follicular lymphoma (FL) biopsies and their functional unresponsiveness that could limit the favorable impact of CTL on disease progression. We report a high percentage of CD8+TIM-3+T cells in lymph nodes of FL patients. When compared to their CD8+TIM-3- counterparts, CD8+TIM-3+ T cells exhibited defective cytokine production following TCR engagement. Furthermore, CD8+TIM-3+ T cells display ex vivo markers of lytic granule release and remain unresponsive to further TCR-induced activation of the lytic machinery. Although confocal microscopy showed that TIM-3 expression on CD8+ T cells correlated with minor alterations of immunological synapse, a selective reduction of ERK signaling in CD8+TIM-3+T cells was observed by phospho-flow analysis. Finally, short relapse-free survival despite rituximab(R)-chemotherapy was observed in patients with high content of TIM-3+ cells and a poor infiltrate of granzyme B+ T cells in FL lymph nodes. Together, our data indicate that, besides selective TCR early signaling defects, TIM-3 expression correlates with unresponsiveness of ex vivo CD8+ T cells in FL. They show that scores based on the combination of exhaustion and cytolytic markers in FL microenvironment might be instrumental to identify patients at early risk of relapses following R-chemotherapy.

Keywords: CD8+ T cell dysfunction; T cell exhaustion; TCR signaling impairment; TIM-3 immune-checkpoint; follicular lymphoma; immunological synapse; prognostic value.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
TIM-3 is highly expressed in both CD8+ and CD8+GrzB+tumor-infiltrating T cells in FL lymph nodes. Percentage of CD3+CD8+TIM-3+ T cells (A) and TIM-3 median fluorescence intensity (B) in CD3+CD8+ T cells from FL nodes (n = 33) and tonsils (n = 29). Percentage of CD3+CD8+GrzB+TIM-3+ T cells (C) and TIM-3 median fluorescence intensity in TIM-3+ CTL cells (D) in FL nodes and tonsils. Example of the gating strategy used and representative histogram of TIM-3 expression in CD8+GrzB+ in FL lymph nodes (E) and in tonsils (F). Unpaired Student's t-test using the GraphPad Prism software (version 6; GraphPad) was used to determine the statistical significance of differences between the groups. p = 0.0002 (A); p = 0.0164 (B); p = 0.0015 (C); p = 0.0078 (D).
Figure 2.
Figure 2.
Impact of TIM-3 expression on cytokine production and lytic machinery activation in FL lymph node CD8+ T cells following TCR triggering. IFNγ (A) and TNFα (B) production by CD8+TIM-3+or by CD8+TIM-3 T cells from FL lymph node cell suspensions (n = 26) after 4 h conjugation with unpulsed or SAg-pulsed EBV B cells. CD107a exposure (C) and GrzB expression (D) in CD8+TIM-3+or CD8+TIM-3 T cells in FL cell suspensions after conjugation. Wilcoxon signed-rank test using the GraphPad Prism software (version 6; GraphPad) was used to determine the statistical significance of differences between the groups. p = 0.0206, 0.0012, 0.0027 (A); p = 0.0252, 0.0002, 0.0261 (B); p = 0.0332, 0.0206, 0.0002 (C); p = 0.3301, 0.3684, 0.0853 (D).
Figure 3.
Figure 3.
Minor alteration of immunological synapse formation in CD8+TIM-3+ T cells from FL lymph nodes. Representative IS formation between CD8+TIM–3+ T cells (A) and CD8+TIM-3– T cells (B and C) from FL lymph nodes (n = 3) stained with α-tubulin (green) and pTyr (red) after 15 min conjugation with unpulsed (C) or SAg-pulsed (A and B) EBV B cells (blue stained). The yellow arrow indicates the MTOC position. Bar 5 µm. (D) Scheme depicting pTyr intensity measurement defined by three reference areas at different regions of the T cell surface: immunological synapse between T cell and target B cell (=IS), distal synapse region (=D–IS) and area between these two regions (=M). The intensity of pTyr red fluorescence was measured in the different cell areas as indicated in the scheme. Fluorescence intensity in the regions of interest was compared to that of the entire cells using the Metamorph® software. In particular, the mean intensity of pTyr red fluorescence in CD8+TIM-3 and in CD8+TIM3+ T cells was calculated by dividing the pTyr red pixels in IS and those in the D-IS for the total red pixel of entire cell (IS+M+D-IS) (E). Comparison of pTyr staining lenght at the IS area between pulsed CD8+TIM-3+ T cells and CD8+TIM-3 T cells (unpulsed CD8+TIM-3– T cells as negative control) (µm). (F) Comparison of the distance between microtubule-organizing center (MTOC) and the center of the IS area between pulsed CD8+TIM-3+ T cells and CD8+TIM-3 T cells (µm). Each dot in Fig. 3D–F represents a cell. Data are from three FL patients. For the different FL samples standardized conditions for pinhole size, for gain and offset (brightness and contrast), were used for image capture. Wilcoxon signed-rank test using the GraphPad Prism software (version 6; GraphPad) was used to determine the statistical significance of differences between the groups. p = 0.3699, p < 0.0001, and p < 0.0001, respectively (D); p < 0.0001 and p = 0.0232, respectively (E).
Figure 4.
Figure 4.
Selective signaling defects following FL CD8+ TIM-3+ T cell stimulation. Representative histogram overlay (A) and pooled datas (B) of CD8+TIM-3+ and CD8+TIM-3T cells staining for phosphorylated ERK (pERK) and AKT (T308 and S473) (pAKTs), (MFI), after 15 min of PMA/ion stimulation (n = 7). Representative histogram overlay (C) and pooled datas (D) of CD8+TIM-3+ and CD8+ TIM-3 T cell staining for pERK after 15 min of TCR triggering (n = 4). Paired Student's t-test using the GraphPad Prism software (version 6; GraphPad) was used to determine the statistical significance of differences between the groups. p = 0.0488 (B); p = 0.0422 (D).
Figure 5.
Figure 5.
Correlation of TIM-3 expression in FL microenvironment with progression-free-survival in FL patients treated by R-combined chemotherapy. Representative sections from FL lymph nodes showing high (A and B) and low (C and D) content of TIM-3+ cells, with cutoff of 10% (bar = 50 µm). Kaplan Meier curves for PFS of FL patients (n = 46) according to GrzB score ( p = 0.016) (E); to the percentage of TIM-3+ cells (p = 0.037) (F) and to the cumulative value of GrzB score and TIM-3 staining in the four groups (Log rank p-value = 0.0064) (G).

References

    1. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J et al.. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105:1417-23; PMID:15494430; http://dx.doi.org/10.1182/blood-2004-08-3175 - DOI - PubMed
    1. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S et al.. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725-32; PMID:16123223; http://dx.doi.org/10.1182/blood-2005-01-0016 - DOI - PubMed
    1. Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF, Haioun C, Brice P, Mahé B, Bouabdallah R et al.. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112:4824-31; PMID:18799723; http://dx.doi.org/10.1182/blood-2008-04-153189 - DOI - PubMed
    1. Alvaro T, Lejeune M, Salvadó MT, Lopez C, Jaén J, Bosch R, Pons LE. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24:5350-7; PMID:17135637; http://dx.doi.org/10.1200/JCO.2006.06.4766 - DOI - PubMed
    1. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM et al.. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351:2159-69; PMID:15548776; http://dx.doi.org/10.1056/NEJMoa041869 - DOI - PubMed

Publication types

LinkOut - more resources